Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for CNV secondary to Pathological Myopia
NCT01037348Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Primary completion
- May 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in choroidal neovascularization (CNV), sponsored by Novartis. Started Jan 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01037348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037348.